Abstract:Background: Amyloid-beta (Abeta)-directed antibodies tested clinically for therapeutic activity against Alzheimer disease (AD) have shown varying degrees of efficacy. Although all of these antibodies target the Abeta peptide, their binding profile to different molecular species of Abeta differs and may underlie the observed variability in clinical outcomes. Objective: Explore the relationship between targeting of soluble toxic Abeta species and therapeutic efficacy. Methods: Surface plasmon resonance (SPR) was used to conduct a side-by-side comparison of the binding of various Abeta-directed antibodies to monomers and soluble Abeta oligomers from AD brains. Immunohistochemistry was performed to assess reactivity with plaque. Preclinical activity was assessed in human amyloid precursor protein (APP) transgenic mouse models of AD. Results: Non-selective, pan-Abeta reactive antibodies such as crenezumab and gantenerumab, which have failed to produce a clinical benefit, bound all forms of Abeta tested. In a competition assay, these antibodies lost the ability to bind toxic AD brain oligomers when exposed to monomers. Aggregate-selective antibodies such as aducanumab, lecanemab and donanemab, showed reduced monomer binding and a greater ability to withstand monomer competition which correlated with their reported inhibition of cognitive decline. Of the antibodies in earlier stages of clinical testing, ACU193 and PMN310 displayed the greatest ability to retain binding to toxic AD brain oligomers while PRX h2731 was highly susceptible to monomer competition. Plaque binding was observed with all aggregate-reactive antibodies with the exception of PMN310, which was strictly selective for soluble oligomers. Targeting of oligomers by PMN310 protected cognition and was not associated with microhemorrhages in mouse models of AD. Conclusions: Overall, these results suggest that selectivity for soluble toxic Abeta oligomers may be a driver of clinical efficacy, with a potentially reduced risk of ARIA if engagement with plaque is minimized.

Computational Investigation of Gantenerumab and Crenezumab Recognition of Aβ Fibrils in Alzheimer's Disease Brain Tissue.

Single-molecule characterisation of soluble beta-amyloid aggregate binding by Aducanumab, Lecanemab, Gantenerumab, and Donanemab

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns

An Enzyme-Linked Immunosorbent Assay To Compare The Affinity Of Chemical Compounds For Beta-Amyloid Peptide As A Monomer

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

Computational Analysis for the Rational Design of Anti-Amyloid Beta (ABeta) Antibodies

Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β

Native ion mobility‐mass spectrometry reveals the binding mechanisms of anti‐amyloid therapeutic antibodies

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

An enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β-amyloid peptide as a monomer

Structural biology of cell surface receptors implicated in Alzheimer’s disease

Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules

Alzheimer's Disease Immunotherapy and Mimetic Peptide Design for Drug Development: Mutation Screening, Molecular Dynamics, and a Quantum Biochemistry Approach Focusing on Aducanumab::Aβ2-7 Binding Affinity

Re-Engineering Therapeutic Anti-Aβ Monoclonal Antibody to Target Amyloid Light Chain

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease

Characterization of a new set of monoclonal β-amyloid antibodies

Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer’s Disease

Real-time analysis of the biomolecular interaction between gelsolin and Aβ1-42 monomer and its implication for Alzheimer's disease

Human Anti-Beta-Amyloid Antibodies Block Beta-Amyloid Fibril Formation and Prevent Beta-Amyloid-Induced Neurotoxicity